department of pharmacology

Stanton L. Gerson, M.D.

Gerson

 

Professor of Hematology and Oncology, Director of Cancer Center

UH/Wearn 151
Case Western Reserve University

Mailing Address:

UH/Wearn 151
10900 Euclid Ave.
Cleveland, Ohio 44106

Phone: (216) 844-8565
E-mail: slg5@case.edu

Research

Dr. Gerson's laboratory's long-standing interest is in evaluating the role of the DNA repair protein O6 alkyguanine-DNA alkyltransferase. One focus is its role in tumor drug resistance to nitrosoureas. He has been a leader in the discovery and development of the AGT modulator O6 benzylguanine. He has demonstrated the efficacy of O6 benzylguanine as a modulator in colon and breast cancer models. This observation has now been extended to a variety of other tumor types and has recently led to the introduction of O6 benzylguanine to the clinic as a modulator of AGT-directed DNA repair. The second focus is in gene therapy using AGT overexpression to protect bone marrow from chemotherapy; a clinical gene therapy is now underway. With Dr. Lili Liu, he has evaluated methoxyamino, an inhibitor of base excision repair, as a potentiator of methylating agent chemotherapy. Dr. Gerson plays an active role in the development of new therapeutics as the Associate Director for Clinical Research.

SELECTED REFERENCES:

Zielske SP, Reese JS, Lingas KT, Donze JR, Gerson SL. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning Journal of Clinical Investigation 112 (10):1561-1570 11/2003.

Zielske SP, Reese JS, Gerson SL Limited Lentiviral Transgene Expression with Increasing Copy Number in an MGMT Selection Model: Lack of Copy Number Selection by Drug Treatment. Molecular Therapy 9 (6): 923-931, 6/04.

Gerson, SL MGMT: Its role in Cancer Aetiology and Cancer Therapeutics. Nature Rev Cancer 4(4) 296-307.